Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Circ Cardiovasc Imaging. 2016 Dec;9(12):e003584. doi: 10.1161/CIRCIMAGING.115.003584

Figure 6.

Figure 6

A) Serial ECV values in DOX-treated and placebo-treated animals over time showing an increase in the ECV at 10 weeks and 20 weeks as compared with the placebo (P < 0.001 for ANOVA, * = P < 0.05 for between group comparisons); B) Cardiac sections stained with trichrome for detection of fibrosis with representative sections from placebo (a) and DOX-treated (b) mouse at 5 weeks and again at 10 weeks [placebo (c), DOX (d)] showing that myocardial fibrosis did not change at 5 weeks but increased by 10 weeks.

C) There was a strong association between the CMR-measured ECV and the extent of myocardial fibrosis by histology; D) Strong correlation between the early increase in edema at 5 weeks and the subsequent increase in fibrosis by ECV at 10 weeks.